Physical activity and the risk of non-Hodgkin lymphoma subtypes: A pooled analysis

Terry Boyle, Geffen Kleinstern, Paige M. Bracci, James R. Cerhan, Yolanda Benavente, Delphine Casabonne, Brian C.H. Chiu, Thomas M. Habermann, Elizabeth A. Holly, Mark Liebow, Aaron Norman, Ora Paltiel, Dennis Robinson, Nathaniel Rothman, Rania Abu Seir, Susan L. Slager, Paul J. Villeneuve, Sophia S. Wang, Dennis D. Weisenburger, John J. Spinelli

Research output: Contribution to journalArticlepeer-review

Abstract

Non-Hodgkin lymphoma (NHL) is composed of a heterogeneous collection of subtypes with considerable differences in genetics, biology and aetiology. Studies to date on physical activity and NHL risk have not had sufficient sample size to evaluate whether associations differ by subtype. We pooled data from nine case-control studies to examine the association between moderate-to-vigorous intensity physical activity (MVPA) and risk of NHL overall and by subtype (diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia/small lymphocytic lymphoma, marginal zone lymphoma and mature T-cell lymphoma). A total of 5653 cases and 9115 controls were included in the pooled analysis. Physical activity was harmonised across nine studies and modelled as study-specific tertiles. Multinomial logistic regression was used to estimate the association between physical activity and NHL, adjusting for confounders. The overall odds of NHL was 13% lower among participants in the most active tertile of MVPA compared to the least active tertile (adjusted odds ratio = 0.87, 95% CI = 0.80, 0.95). Similar decreases were observed across NHL subtypes. In summary, in this pooled analysis of case-control studies, physical activity was associated with a modest risk reduction for each NHL subtype examined and with overall NHL.

Original languageEnglish
JournalInternational Journal of Cancer
DOIs
StateAccepted/In press - 2022

Bibliographical note

Funding Information:
Agència de Gestió d'Ajuts Universitaris i de Recerca; American Institute for Cancer Research, Grant/Award Number: 99B083; California Department of Public Health; Canadian Institutes of Health Research, Grant/Award Number: 300068; Centers for Disease Control and Prevention, Grant/Award Number: U55/CCR921930‐02; Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública; CERCA Programme/Generalitat de Catalunya, Grant/Award Number: 2017SGR1085; Hadassah University Hospital Compensatory Fund; Henry J. Predolin Foundation for Research in Leukemia; Instituto de Salud Carlos III, Grant/Award Number: PMP15/00007; Israel Science Foundation, Grant/Award Number: 877/10; Michael Smith Foundation for Health Research, Grant/Award Number: 5553; National Cancer Institute, Grant/Award Numbers: N01‐PC‐67008, CA087014, CA143947, N01‐PC‐35136, N01‐PC‐65064, N01‐PC‐67009, N01‐PC‐67010, N02‐PC‐71105, P01 CA017054, P30 CA033572, P50 CA97274, R01 CA166219, R01 CA92153, R01CA033572, R01CA100555; National Cancer Institute of Canada; National Health and Medical Research Council, Grant/Award Number: 1072266; Spanish Ministry of Economy and Competitiveness‐Carlos III Institute of Health co‐funded by FEDER funds/European Regional Development Fund (ERDF), Grant/Award Numbers: IJCI‐2016‐29502, PI09/1662, PI11/01810, PI11/02213, PI14/01219, PI15/00966, PI17/01280, RCESP C03/09, RD12/0036/0056, RTIC RD06/0020/0095, RTICESP C03/10, Rio Hortega CM13/00232, SV‐09‐CLINIC‐1; United States Agency for International Development, Grant/Award Number: TA‐MOU‐11‐M31‐025 Funding information

Funding Information:
Terry Boyle was supported by fellowships from the Canadian Institutes of Health Research (#300068), the Australian National Health and Medical Research Council (#1072266), the Michael Smith Foundation for Health Research (#5553) and Killam Trusts. The British Columbia study was supported by the National Cancer Institute of Canada and the Canadian Institutes of Health Research. The City of Hope's Los Angeles NHL Case‐Control study was made possible through funding by the National Cancer Institute grants R01 CA166219, P01 CA017054, R01CA033572 and P30 CA033572. The Israel‐West Bank study was supported by the American people through a grant from the United States Agency for International Development (USAID), MERC grant #TA‐MOU‐11‐M31‐025. The contents are the responsibility of the authors and do not necessarily reflect the views of USAID or the United States Government; Israel Science Foundation (ISF) grant #877/10 and the Hadassah University Hospital Compensatory Fund. The Mayo Clinic study was funded by the National Cancer Institute/National Institutes of Health (R01 CA92153 and P50 CA97274) and the Henry J. Predolin Foundation. The MCC‐Spain study was supported by the Spanish Ministry of Economy and Competitiveness—Carlos III Institute of Health cofunded by FEDER funds/European Regional Development Fund (ERDF)—a way to build Europe (grants PI17/01280, PI11/01810, PI14/01219, PI11/02213, PI09/1662, PI15/00966, RCESP C03/09, RTICESP C03/10, RTIC RD06/0020/0095, RD12/0036/0056, Rio Hortega CM13/00232, Juan de la Cierva de Incorporacion IJCI‐2016‐29502 and SV‐09‐CLINIC‐1), Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP, Spain) and Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), CERCA Programme/Generalitat de Catalunya for institutional support(2017SGR1085) and European Regional Development Fund‐ERDF/FEDER. Some of the participants in the MCC‐Spain study are part of the International Cancer Genome Consortium (ICGC) on CLL, funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto de Salud Carlos III (ISCIII), PMP15/00007 which is part of Plan Nacional de I + D + I and is cofinanced by the ISCIII‐Sub‐Directorate General for Evaluation and the European Regional Development Fund (FEDER‐“Una manera de Hacer Europa”) and CIBERONC. The NCI‐SEER study was funded by the Intramural Research Program of the National Cancer Institute/National Institutes of Health and Public Health Service (contracts N01‐PC‐65064, N01‐PC‐67008, N01‐PC‐67009, N01‐PC‐67010 and N02‐PC‐71105). The Nebraska NHL Study was supported by the American Institute for Cancer Research (99B083) and National Cancer Institute (R01CA100555). The San Francisco study was funded by grants CA087014 and CA143947 from the National Cancer Institute, National Institutes of Health. The collection of cancer incidence data was supported by the California Department of Public Health as part of the state‐wide cancer reporting programme; the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract N01‐PC‐35136 awarded to the Northern California Cancer Center and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement #U55/CCR921930‐02 awarded to the Public Health Institute.

Publisher Copyright:
© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Keywords

  • epidemiology
  • non-Hodgkin lymphoma
  • physical activity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Physical activity and the risk of non-Hodgkin lymphoma subtypes: A pooled analysis'. Together they form a unique fingerprint.

Cite this